Exchange: NASDAQ·Updated 08:10 AM EDT
Upcoming Earnings: Q3 '26

Reports: Aug 13Pre-Market

Estimated EPS

-$0.58

Estimated Rev

$2.55M

$NMTC Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.25 up 43.18% YoY • Reported revenue of $2.39M up 72.46% YoY • NeuroOne expects commercial availability of its drug delivery system in the second half of fiscal 2026 for investigational clinical or animal studies. NeuroOne also remains bullish on ISO 13485 certification in the latter part of 2026.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.58
--
--
N/A
Q2 '26
-$0.23
-$0.25
-10.29%
MISSED
Q1 '26
-$0.03
--
--
N/A
Q4 '25
-$0.03
-$0.05
-66.67%
MISSED
Q3 '25
-$0.05
-$0.03
40.00%
BEAT

Advertisement|Remove ads.